Sling Therapeutics, Inc.
A clinical-stage biotechnology company developing an oral drug candidate for thyroid eye disease.
$123MSeries C
LeadF
Forbion
Activity from announced rounds
Activity in this selectionSep 30, 2026 · Sep 1, 2026
Forbion is an investment firm whose official portfolio and financing news identify CellCentric, Sling and Solstice.
Recorded funding activity
Sling develops an oral medicine for thyroid eye disease. Solstice advances an engineered cancer-immunotherapy antibody, while RQ Bio develops preventive antibodies for vulnerable patients facing influenza. These are separate clinical programs and company financings.
Sources
- Rounds participated in
- 2
- Confirmed lead rounds
- 1 All roles disclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $348M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionSolstice Oncology
A clinical-stage immunotherapy company is advancing an engineered CTLA-4 antibody for earlier cancer treatment.
$225MSeries A
Participant